Myocardial infarction and heart failure magnetic microparticle microfluidic biochip and detection method

Abstract

The invention relates to a myocardial infarction and heart failure magnetic microparticle microfluidic biochip, which belongs to the technical field of POCT detection. The myocardial infraction and heart failure magnetic microparticle microfluidic biochip comprises a PCB board, wherein the PCB board is provided with a microflow passage, a biosensor is arranged in the microflow passage, the biosensor consists of a wafer platform and a point sample antibody covered on the wafer platform, the point sample antibody can form an immune complex with a magnetic bead coupling antibody and a marker protein, and the concentration of the marker protein can be judged by determining a magnetic resistance signal on the wafer platform. In the technical scheme, the magnetic bead has a larger specific surface area, and by combining more antibodies, the detection sensitivity is improved, and the specificity is higher than that of a fourth-generation chemical luminescent method. The invention also provides a detection method using the biochip. The heart markers such as myocardial infarction and heart failure can be simultaneously and quantitatively detected, the detection lower limit can be improved,and the leakage detection and false negative phenomenon can be effectively avoided.

Description

technical field [0001] The invention relates to a magnetic particle microfluidic biochip, which is mainly used for detecting markers of myocardial infarction and heart failure in blood samples; the invention also provides a detection method using the biochip, which belongs to the technical field of POCT detection. Background technique [0002] Cardiovascular disease is a serious disease that endangers human health and life, and has become the number one killer of human health in the 21st century. According to the "China Cardiovascular Disease Report 2015" and "China Cardiovascular Disease Report 2016" compiled by the National Center for Cardiovascular Diseases, the number of patients with cardiovascular diseases in my country is still growing rapidly. According to statistics, the number of patients with cardiovascular disease was 290 million in 2014, and this number has climbed to 290 million by 2015. According to the report estimates, about 3.5 million people die of cardio...

AI Technical Summary

Problems solved by technology

[0008] The first-generation detection technology competition method (radioimmunoassay, RIA): There are many factors affected, and the RIA sample requires a large amount. Because extraction is usually required before detection, it not only increases the operation steps, but also because the recovery rate of extraction is usually Only 80% to 90%, the coefficient of variation (CV) is relatively large, which reduces the precision of detection;

[0009] The second-generation detection method non-competitive method (radioimmunoassay, RIA): immunoassay using double-antibody sandwich, no extraction, high antibody specificity, its sensitivity, precision and specificity are better than competitive methods, but time-consuming Still long and difficult to apply to automation;

[0010] The third-generation detection method enzyme immunoassay, stationary phase immunochromatography: the double antibody plus core method immunoassay solid phase chroma

Images